EUVIMEDEUVIMED entdecken
Multizentrische Studie

Identifying a therapeutic target for ganciclovir against cytomegalovirus in immunocompromised children

Wenyu Yang, Adam Irwin, Heather Weerdenburg, Brett McWhinney, Theresa Cole, Alice Lei, Xiao Zhu iD, Amanda Gwee iD

British Journal of Clinical Pharmacology · 2025

DOI: 10.1002/bcp.70315 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift British Journal of Clinical Pharmacology, 2025. Verfasst von Wenyu Yang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: Cytomegalovirus Infections, Ganciclovir, Immunocompromised Host, Antiviral Agents. Die Arbeit nennt 27 Literaturangaben. Gefördert von: Shanghai Municipal Health Commission Clinical Research Youth Project, National Natural Science Foundation of China, NHMRC Investigator.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Ganciclovir (GCV) is commonly used to treat cytomegalovirus (CMV) infections in immunocompromised children. Currently, the therapeutic target for effective treatment is unclear: Adult studies suggest that a serum area under the concentration‐time curve (AUC 24h ) ≥40 mg/L·h correlates with effective CMV prevention. The aim of this study was to determine the serum GCV therapeutic target for the treatment of CMV viraemia in immunocompromised children.

Methods

Data from a multicenter retrospective audit of GCV dosing, therapeutic drug monitoring and plasma CMV viral loads in immunocompromised children were analysed using piecewise linear regression to determine viral dynamics during GCV treatment periods. A published population pharmacokinetic model from the same cohort was used to derive post hoc average daily AUC 24h . An E max model was developed in NONMEM to explore the effect of drug exposure on viral dynamics, adjusting for immune status.

Results

Fourteen children with 185 viral loads were included, encompassing 30 periods of viral load increases and 28 periods of decline. The estimated natural viral replication rate was 0.237 log 10 copies/mL/day (doubling time 1.3 days). White cell count (WCC) significantly affected the viral decline rate, with a maximum GCV‐induced viral decline rate of 0.238 log 10 copies/mL/day. The GCV AUC 24h corresponding to 90% maximal replication suppression and elimination effects were approximately 40 and 100 mg/L·h, respectively, when the WCC was 3.7 × 10 9 /L.

Conclusions

A serum GCV AUC 24h target of 40–100 mg/L·h may serve as a preliminary reference for the treatment of CMV infection in immunocompromised children. Notably, the therapeutic target is affected by the individual's immune status.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Cytomegalovirus InfectionsGanciclovirImmunocompromised HostAntiviral AgentsCytomegalovirusHumansChildRetrospective StudiesViral LoadMaleFemaleChild, PreschoolDrug MonitoringAdolescentInfantArea Under CurveModels, BiologicalViremia

Stichwörter der Autor:innen

NONMEMcytomegalovirusganciclovirpaediatricstherapeutic targetviral dynamics

Substanzen

GanciclovirAntiviral Agents

Autor:innen und Institutionen

  • Department of Clinical Pharmacy and Pharmacy Administration, School of Pharmacy, Fudan University, Shanghai, China.
  • Centre for Clinical Research, The University of Queensland, Brisbane, Queensland, Australia.
  • Infection Management and Prevention Service, Queensland Children's Hospital, Brisbane, Queensland, Australia.
  • Children's Cancer Centre, Royal Children's Hospital, Melbourne, Victoria, Australia.
  • Department of Paediatrics, The University of Melbourne, Melbourne, Victoria, Australia.
  • Antimicrobial Group, Murdoch Children's Research Institute, Victoria, Australia.

ORCID-Profile: Xiao Zhu, Amanda Gwee

Förderung

  • Shanghai Municipal Health Commission Clinical Research Youth Project
  • National Natural Science Foundation of China
  • NHMRC Investigator

Zitieren

APA

Yang, W., Irwin, A., Weerdenburg, H., McWhinney, B., Cole, T., Lei, A., Zhu, X., & Gwee, A. (2025). Identifying a therapeutic target for ganciclovir against cytomegalovirus in immunocompromised children. British Journal of Clinical Pharmacology. https://doi.org/10.1002/bcp.70315

Vancouver

Yang W, Irwin A, Weerdenburg H, McWhinney B, Cole T, Lei A, et al. Identifying a therapeutic target for ganciclovir against cytomegalovirus in immunocompromised children. British Journal of Clinical Pharmacology. 2025. doi:10.1002/bcp.70315

BibTeX
@article{Yang2025,
  author = {Yang, Wenyu and Irwin, Adam and Weerdenburg, Heather and McWhinney, Brett and Cole, Theresa and Lei, Alice and Zhu, Xiao and Gwee, Amanda},
  title = {Identifying a therapeutic target for ganciclovir against cytomegalovirus in immunocompromised children},
  journal = {British Journal of Clinical Pharmacology},
  year = {2025},
  doi = {10.1002/bcp.70315}
}
Kostenlos starten →